🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

HuNIRe trial: Multicenter 🇮🇹 RCT evaluating role of re-staging TURBT in HG T1 NMIBC: 🔷TURBT (grossly complete, muscle present)➡️cytology at 4-6 wks & cysto at 6-8 wks➡️If both neg, then BCG; if either positive, then re-staging TURBT 📌68% avoided re-TUR (32% underwent re-TUR)

#ESTRO24 Piet Ost presenting outcomes of STORM randomized Ph II of MDT v ENRT for oligorecurrent prostate cancer #pcsm ✅ ENRT ⬆️BRFS, LRFS MDT a/w 8-fold ⬆️ nodal recurrence 3➡️25% Omitting PB ⬆️ local recurrences 3-fold (5➡️14%), but also increases GU2+ toxicity

#ESTRO2024 #prostatecancer symposium: Optimising TARGET🎯 by Dr Floris Pos 👉FLAME RCT: ⬆️GTV dose better 👉minimum (D98%) GTV dose more imp than mean (D50%), prefer >=90Gy 👉⬆️Gleason needs ⬆️dose

Delighted to see this in print! Urinary and sexual outcomes after radical prostatectomy in 26 UK centres, reporting urine leakage, pad use and erections with & without medication European Urology Open Science Muhieddine Labban Alexander P Cole Quoc-Dien Trinh, MD, MBA @HamerKev eur01.safelinks.protection.outlook.com/?url=https%3A%…

Diary of a Rad Onc Resident. Just came across this tongue-in-cheek 'typical' day in #radonc ! Made me actually laugh out loud! Found it on Reddit.

Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from CIHR to support the #CCTG PR26 (TRIPLE-SWITCH) trial. The study aims to personalize chemotherapy use and improve survival for patients with metastatic #ProstateCancer. bit.ly/4dEXb0H

Do we really need complete TURBT before bladder radiotherapy? Vedang Murthy Prof Ananya💙 @achoud72.bsky.social John Christodouleas redjournal.org/article/S0360-…

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

Happy to announce that the PEACE 6 OligoPRESTO trial testing the role of metastasis directed therapy in hormone sensitive #ProstateCancer has completed accrual ahead of schedule. 550 patients randomized. Waiting now for data to mature.

Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy. pubmed.ncbi.nlm.nih.gov/39264453/

Peter Mac’s radiation oncologist Shankar Siva will be the first Australian to deliver the Presidential Symposium at #ASTRO Congress. Don't miss his lecture ISABR for RCC - Is It Ready For Primetime? on Sept 29.

On Monday, I will present the key PARTIQoL trial results at the 2024 ASTRO Annual Meeting! 🎉 I'll cover the potential benefits of #ProtonTherapy, & innovative patient recruitment strategies. Let me know if you are attending #ASTRO2024 too!

ASTRO abstracts are no longer embargoed after 5PM EST 9/27. Here is LBA1: PARTIQoL, Phase III study of protons vs IMRT for LR/IR prostate cancer. No significant differences in tumor control or patient-reported quality of life out to 60 months of follow up. #radonc

Radiation Oncologist Workload after Traditional Office Hours: A Threat to Work-Life Balance? - #ASTRO24 redjournal.org/article/S0360-… Analysis shows a rather alarming increase in radiation oncologist's workload after-hours between 2015 and 2023.

Tell me again why we can’t use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by Shankar Siva #ASTRO24

🚨Vedang Murthy continues to raise the Bar(t) with randomised trials in GU Cast | Urology podcast! #radiotherapy trials. Adjuvant RT in high risk bladder cancer; 8-year accrual, with good safety signal (acute and late tox). Majority of patients had chemotherapy, pN+ve or T3+ #ASTRO24 #radonc

Congrats Sondos Zayed @drdavidpalma and team… such a great example of a good clinical question turning into an important clinical trial

Superb talk by Chris Goodman on lung RT in patients with ILD/IPF @ #ASTRO24 ➡️complex disease ➡️Interactions between ILD+TRT poorly understood ➡️Screen all patients for ILAs ➡️Consider ILD-GAP index to assist with risk assessment ➡️Robust consent discussions imperative

I've decided that when researchers say a treatment is "well tolerated" it actually means "I can tolerate my patients having toxicity" and nothing to do with what the patient thinks. We can only make such a statement if we use patient-reported outcome or experience measures.

A phase III randomized clinical trial shows better patient-centered outcomes with radiation therapy vs systemic therapy (for breast cancer). An excellent summary by QuadShot News highlights the implications. #radonc thelancet.com/journals/lanon…